Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3

Conditions

Leukemia, Myeloid, Acute 7Myeloproliferative Disorders 3Myelodysplastic Syndromes 2Leukemia, Monocytic, Acute 2Sarcoma, Kaposi 1Rectal Neoplasms 1Leukemia, Myelomonocytic, Chronic 1HIV Infections 1Colorectal Neoplasms 1Colonic Neoplasms 1Breast Cancer Metastatic 1Acquired Immunodeficiency Syndrome 1

Interventions

Cyclophosphamide 53fludarabine phosphate 50Tacrolimus 41Busulfan 41Peripheral Blood Stem Cell Transplantation 37Mycophenolic Acid 36Whole-Body Irradiation 34Antilymphocyte Serum 34Cyclosporine 27Methotrexate 25fludarabine 24Melphalan 20Radiotherapy 19Filgrastim 16Methylprednisolone 14Cord Blood Stem Cell Transplantation 12Cytarabine 11thymoglobulin 10ruxolitinib 10Specimen Handling 10Biopsy 10Cyclosporins 9sargramostim 8Sirolimus 8Etoposide 8Alemtuzumab 8Thiotepa 7Stem Cell Transplantation 7Granulocyte Colony-Stimulating Factor 7Azacitidine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Myeloproliferative Disorders × Liposomes × Clear all
NCT05554406 2026-06-05

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
335 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT04802161 2025-12-19

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

National Cancer Institute (NCI)

Phase 2 Active not recruiting
50 enrolled 12 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡